Analysts Set DRI Healthcare Trust (TSE:DHT.UN) Target Price at C$18.00

DRI Healthcare Trust (TSE:DHT.UN) has been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is C$18.00.

DHT.UN has been the topic of several recent research reports. Raymond James reduced their target price on shares of DRI Healthcare Trust from C$23.00 to C$22.00 in a report on Wednesday, November 13th. Scotiabank raised their price objective on DRI Healthcare Trust from C$21.00 to C$22.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th.

DRI Healthcare Trust Price Performance

DHT.UN opened at C$12.95 on Thursday. The business’s fifty day simple moving average is C$13.41 and its 200 day simple moving average is C$13.37. DRI Healthcare Trust has a 52 week low of C$10.39 and a 52 week high of C$17.43.

DRI Healthcare Trust Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 18th. Investors of record on Friday, October 18th were given a dividend of $0.085 per share. The ex-dividend date of this dividend was Friday, September 27th. This represents a $0.34 dividend on an annualized basis and a yield of 2.63%. DRI Healthcare Trust’s dividend payout ratio (DPR) is currently -920.00%.

About DRI Healthcare Trust

DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.